N-(2-methoxyphenyl)-N'-(2-methyl-4-quinolinyl) urea | 71294-59-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: N-(2-methoxyphenyl)-N'-(2-methyl-4-quinolinyl) urea
• 英文别名: 1-(2-Methoxyphenyl)-3-(2-methylquinolin-4-yl)urea
• CAS: 71294-59-2
• 化学式: C₁₈H₁₇N₃O₂
• 分子量: 307.352
• InChiKey: IETIBXVXLAXJIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  63.2
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] HETEROARYL-ARYL UREAS AS IGF-1 RECEPTOR ANTAGONISTS<br/>[FR] UREES HETEROARYLE-ARYLE UTILISEES COMME ANTAGONISTES DU RECEPTEUR IGF-1
  申请人：TELIK INC

  公开号：WO2000035455A1

  公开（公告）日：2000-06-22

  Methods for treating diseases associated with the activity of the insulin growth factor-1 receptor (IGF-1R), such as cancer, are provided. Methods for inhibiting cell growth and proliferation, especially of tumor cells, and promoting apoptosis are also provided. Each of these methods employs the use of a heteroaryl-aryl urea compound as an antagonist for IGF-1R.

  提供了一种治疗与胰岛素生长因子-1受体（IGF-1R）活性相关的疾病，如癌症的方法。还提供了一种抑制细胞生长和增殖，特别是肿瘤细胞，并促进细胞凋亡的方法。每种方法都使用杂环芳基脲化合物作为IGF-1R的拮抗剂。
• PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1150977A1

  公开（公告）日：2001-11-07
• US6337338B1
  申请人：——

  公开号：US6337338B1

  公开（公告）日：2002-01-08
• US6699879B1
  申请人：——

  公开号：US6699879B1

  公开（公告）日：2004-03-02
• [EN] PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE PHENYLUREE ET DE PHENYLTHIOUREE UTILISES COMME ANTAGONISTES DES RECEPTEURS DE L'OREXINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2000047577A1

  公开（公告）日：2000-08-17

  The present invention provides phenyl urea and phenyl thiourea derivatives which are non-peptide antagonists of human orexin receptors, in particular orexin-1 receptors, of formula (I) in which: Z represents oxygen or sulfur; and R1 to R7 represent various substituent groups; and pharmaceutically acceptable salts thereof. In particular, these compounds are of potential use in the treatment of obesity including obesity observed in Type 2(non-insulin-dependent) diabetes patients and/or sleep disorders.